Loading chat...
HI SCR100
Concurrent Resolution
AI Summary
-
Department of Health requested to establish a Therapeutic Psilocybin Working Group to examine federal, state, and local laws regarding therapeutic psilocybin use and review medical research on psilocybin's safety and efficacy for treating mental health conditions including addiction, depression, anxiety, and end-of-life psychological distress.
-
Working group directed to develop a long-term strategic plan contingent on Food and Drug Administration approval for medical use, aimed at making therapeutic psilocybin or psilocybin-based products safe, accessible, and affordable for adults 21 years of age or older.
-
Working group membership includes the Director of Health as chairperson, Attorney General, Dean of John A. Burns School of Medicine, relevant legislative committee chairs, Hawaii State Council on Mental Health chairperson, a licensed physician or advanced practice registered nurse, and a licensed psychiatrist.
-
Working group required to submit a preliminary report no later than 20 days before the 2023 regular legislative session and a final report with recommendations and proposed legislation no later than 20 days before the 2024 regular legislative session.
-
Working group scheduled for dissolution on July 1, 2024.
Legislative Description
Requesting The Department Of Health To Convene A Therapeutic Psilocybin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Develop A Long-term Strategic Plan, Should Food And Drug Administration Approval For Medical Use Be Obtained, To Enable The Availability Of Therapeutic Psilocybin Or Psilocybin-based Products That Are Safe, Accessible, And Affordable For Adults Twenty-one Years Of Age Or Older.
Department of Health
Last Action
Report adopted; referred to the committee(s) on CPC with Representative(s) Branco voting aye with reservations; none voting no (0) and Representative(s) Hashimoto, McKelvey, Ward excused (3).
4/19/2022